- Home
- Research
- Endocannabinoid
- Endocannabinoid dynamics across marathon and ultramarathon running: evidence from two field studies.
The body’s own cannabinoids shift throughout extreme endurance exercise
Endocannabinoid dynamics across marathon and ultramarathon running: evidence from two field studies.
AI Summary
This research examined how the body’s own endocannabinoid system changes during prolonged endurance exercise. In one study, 19 trained runners completed a marathon and a walking session, with blood samples collected every 14 km and after a 45-minute recovery. A second study followed 36 ultramarathon runners competing over 100 km, 160 km, or 230 km. The researchers measured anandamide (AEA), 2-arachidonoylglycerol (2-AG), and related molecules, alongside feelings of euphoria, anxiety, and pain.
AEA rose progressively during the marathon and stayed elevated into recovery, while walking caused more modest changes. 2-AG increased later in the marathon and after recovery, suggesting a different, delayed role. Marathon running was linked with greater euphoria and lower anxiety than walking, while pain increased during the later stages. Ultramarathons also reduced anxiety and increased pain, but did not significantly change euphoria after exercise. These findings support a time-dependent role for the body’s own cannabinoid signaling in endurance exercise—but they do not show that using cannabis or THC produces the same effects, improves running, or prevents exercise-related pain.
💡 Key Findings
📄
Original Abstract
Related Research
Similar Studies
More Endocannabinoid research papers you might find interesting.
Review links cannabis to possible heart attack mechanisms, not proven risk
Visceral fat endocannabinoid production rose with diabetes, not obesity alone
Targeted CB2 drug delivery reduced mouse plaque deposits, with sex differences
Explore More Research
Stay informed about the latest cannabis science.